Literature DB >> 15668429

Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy.

P Dubey1, A Fatemi, P B Barker, M Degaonkar, M Troeger, K Zackowski, A Bastian, S A Smith, M G Pomper, H W Moser, G V Raymond.   

Abstract

BACKGROUND: Adrenomyeloneuropathy (AMN) is the adult variant of X-linked adrenoleukodystrophy. The disease pathology is usually limited to spinal cord and peripheral nerves, and when this is the case, it is referred to as "pure" AMN. Histopathology shows cerebral involvement even in pure AMN; however, not much is known about the nature, extent, and clinical relevance of these findings.
OBJECTIVE: To investigate brain involvement in AMN patients with normal MRI, employing multislice MR spectroscopic imaging.
METHODS: Twelve men with pure AMN were compared with 19 age-matched healthy volunteers. Metabolite ratios (N-acetylaspartate [NAA]/choline [Cho], NAA/creatine [Cr], and Cho/Cr) were measured from seven brain regions. Global metabolite ratios were generated as an average of these seven regional ratios. The Expanded Disability Status Scale (EDSS) was used for neurologic evaluation.
RESULTS: The patients with AMN showed reduced global NAA/Cho (AMN 1.40 +/- 0.16 vs controls 1.75 +/- 0.34; p = 0.003)) and global NAA/Cr (AMN 2.32 +/- 0.13 vs controls 2.62 +/- 0.43; p = 0.03). Regionally, NAA/Cho was lowered in the internal capsule (AMN 1.30 +/- 0.20 vs controls 1.69 +/- 0.37; p = 0.002) and in parieto-occipital white matter (AMN 1.45 +/- 0.19 vs controls 1.78 +/- 0.55; p = 0.04). NAA/Cr was lowered in parieto-occipital white matter (AMN 2.34 +/- 0.31 vs controls 2.83 +/- 0.71; p = 0.04). EDSS demonstrated an inverse association with global NAA/Cr (r = -0.65, p = 0.02) and NAA/Cr in centrum semiovale (r = -0.73, p = 0.006) and in parieto-occipital white matter (r = -0.64, p = 0.02). Cho/Cr was not significantly elevated.
CONCLUSIONS: (1)H-MR spectroscopic imaging is able to detect biochemical abnormalities suggestive of axonal damage even in the brains of patients with pure adrenomyeloneuropathy. The axonopathy is most prominent in internal capsule and parieto-occipital white matter and may contribute to clinical disability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668429     DOI: 10.1212/01.WNL.0000149514.13580.84

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Therapeutic strategies in adrenoleukodystrophy.

Authors:  Bela R Turk; Ann B Moser; Ali Fatemi
Journal:  Wien Med Wochenschr       Date:  2017-05-10

Review 2.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 3.  Therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser
Journal:  NeuroRx       Date:  2006-04

Review 4.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

5.  Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy.

Authors:  Eva Ratai; Trina Kok; Christopher Wiggins; Graham Wiggins; Ellen Grant; Borjan Gagoski; Gilmore O'Neill; Elfar Adalsteinsson; Florian Eichler
Journal:  Arch Neurol       Date:  2008-11

6.  Mutations, clinical findings and survival estimates in South American patients with X-linked adrenoleukodystrophy.

Authors:  Fernanda dos Santos Pereira; Ursula Matte; Clarissa Troller Habekost; Raphael Machado de Castilhos; Antonette Souto El Husny; Charles Marques Lourenço; Angela M Vianna-Morgante; Liane Giuliani; Marcial Francis Galera; Rachel Honjo; Chong Ae Kim; Juan Politei; Carmen Regla Vargas; Laura Bannach Jardim
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 7.  Peroxisomes in brain development and function.

Authors:  Johannes Berger; Fabian Dorninger; Sonja Forss-Petter; Markus Kunze
Journal:  Biochim Biophys Acta       Date:  2015-12-11

8.  Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy.

Authors:  Aia Elise Jønch; Else Rubæk Danielsen; Carsten Thomsen; Per Meden; Kirsten Svenstrup; Jørgen Erik Nielsen
Journal:  BMC Neurol       Date:  2012-09-26       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.